Micafungin Hikma Farmacêutica (Portugal)

Micafungin, the active ingredient in Micafungin Hikma Farmacêutica, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is employed for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Hikma Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Micafungin is an echinocandin antifungal that targets Candida species in systemic and mucosal infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida. - Prophylaxis in hematopoietic stem cell transplantation: prevents invasive Candida infections in high‑risk transplant recipients.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever - Nausea - Headache - Infusion‑related reactions

Serious or Rare Side Effects: - Hepatic failure - Severe allergic reactions (anaphylaxis) - Renal impairment - Stevens‑Johnson syndrome

Prior to initiating therapy, clinicians should consider several safety measures. - Monitor liver function: obtain baseline and periodic hepatic enzyme tests. - Assess renal function: adjust therapy if significant impairment is present. - Evaluate hypersensitivity: discontinue if signs of severe allergic reaction appear. - Use caution in patients with pre‑existing cardiac disease due to potential infusion‑related hypotension. - Review concomitant hepatotoxic medications: consider dose adjustments or alternative agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole) can increase micafungin plasma levels. - Co‑administration with other echinocandins may heighten toxicity risk. - Concurrent use with strong immunosuppressants may exacerbate infection risk.

Moderate Interactions (Monitor Closely): - Azole antifungals may produce additive antifungal effects; monitor clinical response. - Statins may have increased myopathy risk; observe for muscle symptoms. - Warfarin therapy may experience altered INR; check coagulation parameters regularly. - Anticonvulsants such as carbamazepine may affect micafungin concentrations; adjust dosing if needed.